Tarcocimab demonstrated high efficacy and industry-leading durability in diabetic retinopathy in the Phase 3 GLOW1 study 33 Proportion of patients developing any sight- threatening complication from Baseline to Week 48 Key Secondary Endpoint ~90% risk reduction for developing a pre-specified sight-threatening complication with tarcocimab Primary Endpoint Tarcocimab demonstrated superiority in ≥2-step and ≥3-step improvement in DRSS Proportion of patients with ≥2-Step improvement in DRSS from Baseline to Week 48 100% of patients on 6-month dosing at Year 1 DRSS: diabetic retinopathy severity score; GLOW 1 study NCT05066230; GLOW2 study NCT06270836 1. Roche epidemiology data from 2025 DR GLOW1 Primary endpoint (superiority) 6-month dosing in all patients Approximately 855,000 patients with DR were treated with anti-VEGF agents in the US in 2025, indicating a higher use of anti-VEGF agents than previously estimated 1 Quadrant of core unmet need